Episode 3 (October 30, 2024): Helen Sabzevari, PhD, President and CEO of Precigen, discusses the barriers to implementing cell and gene therapies that impede the accessibility and implementation of these precision medicines. Dr. Sabzevari also explains how key cell and gene therapy platforms and tools can provide safety measures, such as guardrails to cellular toxicity, and address cost by offering “off-the-shelf” efficient gene delivery vectors that can be used on-site, cutting out centralized manufacturing.
You can find the transcription of the interview’s highlights here.
Podden och tillhörande omslagsbild på den här sidan tillhör Inside Precision Medicine. Innehållet i podden är skapat av Inside Precision Medicine och inte av, eller tillsammans med, Poddtoppen.
